Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 4/20 | 0.40 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.39 |
| ▸ | TYMP | P19971 | 2/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 6/20 | 0.32 |
| ▸ | ADK | P55263 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | OGA | O60502 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15549481 | 0.89 | PNP (0.41) | PNPSTING1ALDH1A1MEN1KMT2A | |
| SCHEMBL25680130 | 0.84 | STING1 (0.34) | STING1 | |
| SCHEMBL20393700 | 0.82 | PNP (0.41) | PNPSTING1ALDH1A1MEN1KMT2A | |
| SCHEMBL25680136 | 0.75 | MAPT (0.33) | PNP | |
| SCHEMBL25680127 | 0.74 | — | — | |
| SCHEMBL6838092 | 0.72 | ADORA2A (0.37) | PNPSTING1ALDH1A1 | |
| SCHEMBL20393800 | 0.71 | PNP (0.46) | PNPALDH1A1MEN1KMT2A | |
| SCHEMBL20393704 | 0.71 | STING1 (0.33) | PNPSTING1 | |
| SCHEMBL22990589 | 0.69 | ALDH1A1 (0.46) | STING1ALDH1A1 | |
| SCHEMBL20225022 | 0.69 | ALDH1A1 (0.46) | STING1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | PNP 174/4885STING1 1/4885TYMP 408/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | PNP 174/4885STING1 1/4885TYMP 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.